Literature DB >> 1067055

The problem of the treatment of sarcoidosis: Report of the Subcommittee on Therapy.

J Turiaf, C J Johns, A S Terstein, S Tsuji, K Wurm.   

Abstract

Stage I: Hilar Adenopathy With normal lung function observe, as it often resolves. With reduced lung function observe for 6-12 months. Treat if there is progression or persistence. With erythema nodosum use mild anti-inflammatory agents such as salicylates or like drugs. Stage II: Adenopathy + Pulmonar Infiltrates With normal or slightly reduced lung function observe; treat if it worsens. Treat if there is no remission in 6-12 months. With reduced lung function treat, possibly for many years or a lifetime. Stage III: Pulmonary Infiltrates +/- Fibrosis Without Adenopathy There is reduced lung function. Treat, demonstrate improvement, follow patients with serial measurements of vital capacity at least. Other Indications for Treatment Other indications for treatment include myocardial sarcoidosis, cerebral sarcoidosis (although the outcome is less certain), serious hepatic or renal sarcoidosis, hypercalcemia, persistent systemic symptoms, or other serious organ or functional impairment. Assess each patient individually and completely. Use good clinical judgement. It is clear that treatment that is too little or too late is of little benefit. Even the statistical results form a perfectly controlled study cannot provide absolute direction for the individual patient. As clinicians we are frequently called upon to apply considered judgements without hard data to predict the outcome. We also maintain the flexibility to change our therapeutic programs when circumstances change, either in the patient or in our knowledge. We can be grateful we have a treatment as good as corticosteroids and must try to exercise our best judgement as to when it should be instituted.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1067055     DOI: 10.1111/j.1749-6632.1976.tb47091.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Neurosarcoidosis presenting in the pituitary gland with normal endocrine studies.

Authors:  J E Arle; A R Judkins; M J Kotapka
Journal:  Skull Base Surg       Date:  1999

Review 2.  Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations.

Authors:  M Sekiguchi; Y Yazaki; M Isobe; M Hiroe
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

3.  Pulmonary sarcoidosis with an alveolar radiographic pattern.

Authors:  J P Battesti; G Saumon; D Valeyre; J Amouroux; B Pechnick; D Sandron; R Georges
Journal:  Thorax       Date:  1982-06       Impact factor: 9.139

4.  Pulmonary histiocytosis X in adult patients.

Authors:  D Huhn; G König; J Weig; W Schneller
Journal:  Klin Wochenschr       Date:  1981-04-15

5.  Multisystemic Sarcoidosis Revealed by Hepatosplenomegaly: A Case Report.

Authors:  Fatima Zahra El Rhaoussi; Soukaina Banani; Sophia Bouamama; Nissrine Bennani; Wafaa Badre
Journal:  Cureus       Date:  2022-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.